FDA approves minimally invasive surgical device for treating urinary tract symptoms

The FDA approved the Optilume BPH catheter system, a minimally invasive surgical therapy used for the treatment of lower urinary tract symptoms.

The treatment was developed by Urotronic, a medical technology company that specializes in treating urological conditions, and uses a drug-coated balloon to treat benign prostatic hyperplasia by dilating the urethra and allowing improved urine flow, Urotronic said in a July 11 news release.

The system results in substantial, immediate improvements in BPH patient symptoms and functions that was maintained throughout the four-year follow-up period, according to findings from clinical trials.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast